Highlights

  • Anteris Technologies Global is developing the DurAVR transcatheter valve for aortic stenosis.
  • The PARADIGM trial is central to the company’s clinical programme.
  • The company appointed a new chief financial officer in September 2026.
  • Anteris completed US$320 million of Capital raisings during January 2026.
  • The company continues expanding Manufacturing and clinical activities.

Anteris Technologies Global Corp (ASX:AVR) is a structural heart company developing the DurAVR transcatheter valve for aortic stenosis. The company is progressing clinical, manufacturing and operational activities as it advances its medical device programme.

Recent Development

On 7 September 2026, Anteris announced the appointment of Brent Moen as chief financial officer. The appointment occurred while the company continued scaling manufacturing and clinical operations across multiple jurisdictions.

Clinical Programme

The PARADIGM trial is a prospective randomised controlled study comparing DurAVR against commercially available TAVR devices. The study targets an all-comers cohort of approximately 1,000 patients and has a one-year primary endpoint.

Financial and Operational Position

Anteris completed US$320 million of capital raisings during January 2026 to support the pivotal trial and commercial preparation. Net operating cash outflow was US$28.7 million in the March 2026 quarter and US$20.8 million in the June 2026 quarter.

Key Risks

Clinical trials involve uncertainty around enrolment, outcomes and regulatory requirements. The company continues to require funding to support clinical and operational activities.

Key Insights

Anteris Technologies Global’s current focus remains on progressing DurAVR through clinical development. Future updates will provide further information on trial enrolment, manufacturing progress and operational execution.